264 related articles for article (PubMed ID: 20065059)
1. Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers.
Bulitta JB; Landersdorfer CB; Hüttner SJ; Drusano GL; Kinzig M; Holzgrabe U; Stephan U; Sörgel F
Antimicrob Agents Chemother; 2010 Mar; 54(3):1275-82. PubMed ID: 20065059
[TBL] [Abstract][Full Text] [Related]
2. Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers.
Bulitta JB; Duffull SB; Kinzig-Schippers M; Holzgrabe U; Stephan U; Drusano GL; Sörgel F
Antimicrob Agents Chemother; 2007 Jul; 51(7):2497-507. PubMed ID: 17485505
[TBL] [Abstract][Full Text] [Related]
3. Comparable population pharmacokinetics and pharmacodynamic breakpoints of cefpirome in cystic fibrosis patients and healthy volunteers.
Bulitta JB; Kinzig M; Landersdorfer CB; Holzgrabe U; Stephan U; Sörgel F
Antimicrob Agents Chemother; 2011 Jun; 55(6):2927-36. PubMed ID: 21402834
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis.
Bensman TJ; Wang J; Jayne J; Fukushima L; Rao AP; D'Argenio DZ; Beringer PM
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784670
[TBL] [Abstract][Full Text] [Related]
5. A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit.
Mouton JW; Punt N; Vinks AA
Clin Ther; 2005 Jun; 27(6):762-72. PubMed ID: 16117983
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the pharmacokinetics and pharmacodynamic profile of carumonam in cystic fibrosis patients and healthy volunteers.
Bulitta JB; Duffull SB; Landersdorfer CB; Kinzig M; Holzgrabe U; Stephan U; Drusano GL; Sörgel F
Diagn Microbiol Infect Dis; 2009 Oct; 65(2):130-41. PubMed ID: 19748423
[TBL] [Abstract][Full Text] [Related]
7. Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation.
Monogue ML; Pettit RS; Muhlebach M; Cies JJ; Nicolau DP; Kuti JL
Antimicrob Agents Chemother; 2016 Nov; 60(11):6578-6584. PubMed ID: 27550351
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of continuous-infusion ceftazidime in febrile neutropenic children undergoing HSCT: implications for target attainment for empirical treatment against Pseudomonas aeruginosa.
Cojutti PG; Maximova N; Schillani G; Hope W; Pea F
J Antimicrob Chemother; 2019 Jun; 74(6):1648-1655. PubMed ID: 30838391
[TBL] [Abstract][Full Text] [Related]
9. New semiphysiological absorption model to assess the pharmacodynamic profile of cefuroxime axetil using nonparametric and parametric population pharmacokinetics.
Bulitta JB; Landersdorfer CB; Kinzig M; Holzgrabe U; Sorgel F
Antimicrob Agents Chemother; 2009 Aug; 53(8):3462-71. PubMed ID: 19528278
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model.
Cappelletty DM; Kang SL; Palmer SM; Rybak MJ
Antimicrob Agents Chemother; 1995 Aug; 39(8):1797-801. PubMed ID: 7486921
[TBL] [Abstract][Full Text] [Related]
11. Superiority of ceftazidime off-label high-dose regimen in PK/PD target attainment during treatment of extensively drug-resistant Pseudomonas aeruginosa infections in cancer patients.
Zavrelova A; Sima M; Malakova J; Rozsivalova P; Paterova P; Zak P; Visek B; Michalickova D; Slanar O; Radocha J
Br J Clin Pharmacol; 2023 Apr; 89(4):1452-1461. PubMed ID: 36422512
[TBL] [Abstract][Full Text] [Related]
12. Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection.
Moriarty TF; McElnay JC; Elborn JS; Tunney MM
Pediatr Pulmonol; 2007 Nov; 42(11):1008-17. PubMed ID: 17902147
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics at two dose levels and pharmacodynamic profiling of flucloxacillin.
Landersdorfer CB; Kirkpatrick CM; Kinzig-Schippers M; Bulitta JB; Holzgrabe U; Drusano GL; Sörgel F
Antimicrob Agents Chemother; 2007 Sep; 51(9):3290-7. PubMed ID: 17576847
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations.
Butterfield JM; Lodise TP; Beegle S; Rosen J; Farkas J; Pai MP
J Antimicrob Chemother; 2014 Jan; 69(1):176-9. PubMed ID: 23869050
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of Telavancin in Adult Patients with Cystic Fibrosis during Acute Pulmonary Exacerbation.
Kidd JM; Sakon CM; Oleksiuk LM; Cies JJ; Pettit RS; Nicolau DP; Kuti JL
Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31685468
[TBL] [Abstract][Full Text] [Related]
16. Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure.
Pea F; Viale P; Damiani D; Pavan F; Cristini F; Fanin R; Furlanut M
Antimicrob Agents Chemother; 2005 Aug; 49(8):3550-3. PubMed ID: 16048982
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of ceftazidime in critically ill children: impact of cystic fibrosis.
Bui S; Facchin A; Ha P; Bouchet S; Leroux S; Nacka F; Fayon M; Jacqz-Aigrain E
J Antimicrob Chemother; 2020 Aug; 75(8):2232-2239. PubMed ID: 32457995
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetic and pharmacodynamic modeling of high-dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients.
Zobell JT; Stockmann C; Young DC; Cash J; McDowell BJ; Korgenski K; Sherwin CM; Spigarelli M; Chatfield BA; Ampofo K
Clin Ther; 2011 Nov; 33(11):1844-50. PubMed ID: 22018680
[TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacokinetics of meropenem and biapenem in bile and dosing considerations for biliary tract infections based on site-specific pharmacodynamic target attainment.
Ikawa K; Nakashima A; Morikawa N; Ikeda K; Murakami Y; Ohge H; Derendorf H; Sueda T
Antimicrob Agents Chemother; 2011 Dec; 55(12):5609-15. PubMed ID: 21947393
[TBL] [Abstract][Full Text] [Related]
20. Comparison of pharmacodynamic target attainment between healthy subjects and patients for ceftazidime and meropenem.
Kuti JL; Horowitz S; Nightingale CH; Nicolau DP
Pharmacotherapy; 2005 Jul; 25(7):935-41. PubMed ID: 16006272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
